555 related articles for article (PubMed ID: 26895767)
1. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
Sonesson C; Johansson PA; Johnsson E; Gause-Nilsson I
Cardiovasc Diabetol; 2016 Feb; 15():37. PubMed ID: 26895767
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL
Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Persson F; Nyström T; Jørgensen ME; Carstensen B; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Eriksson JW; Norhammar A; Bodegard J; Birkeland KI
Diabetes Obes Metab; 2018 Feb; 20(2):344-351. PubMed ID: 28771923
[TBL] [Abstract][Full Text] [Related]
5. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Shigiyama F; Kumashiro N; Fuchigami A; Hirose T
Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Kosiborod M; Gause-Nilsson I; Xu J; Sonesson C; Johnsson E
J Diabetes Complications; 2017 Jul; 31(7):1215-1221. PubMed ID: 28284707
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
O'Donoghue ML; Kato ET; Mosenzon O; Murphy SA; Cahn A; Herrera M; Tankova T; Šmahelová A; Merlini P; Gause-Nilsson I; Langkilde AM; McGuire DK; Wilding JPH; Leiter LA; Bhatt DL; Raz I; Sabatine MS; Wiviott SD
Diabetologia; 2021 Jun; 64(6):1226-1234. PubMed ID: 33611623
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
[TBL] [Abstract][Full Text] [Related]
11. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
[TBL] [Abstract][Full Text] [Related]
13. Effects of dapagliflozin on cardiovascular risk factors.
Ptaszynska A; Hardy E; Johnsson E; Parikh S; List J
Postgrad Med; 2013 May; 125(3):181-9. PubMed ID: 23748519
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Norhammar A; Bodegård J; Nyström T; Thuresson M; Nathanson D; Eriksson JW
Diabetes Obes Metab; 2019 May; 21(5):1136-1145. PubMed ID: 30609272
[TBL] [Abstract][Full Text] [Related]
16. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
[TBL] [Abstract][Full Text] [Related]
17. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
[TBL] [Abstract][Full Text] [Related]
18. DECLARE-TIMI 58: Participants' baseline characteristics.
Raz I; Mosenzon O; Bonaca MP; Cahn A; Kato ET; Silverman MG; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Langkilde AM; Johansson PA; Sabatine MS; Wiviott SD
Diabetes Obes Metab; 2018 May; 20(5):1102-1110. PubMed ID: 29322605
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]